Clinical Trial Update: A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial assessing Linvoseltamab in adults with high-risk Monoclonal Gammopathy of Undetermined Significance or non-high-risk Smoldering M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Smoldering Multiple Myeloma

Drugs mentioned

• Linvoseltamab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | Status: RECRUITING